Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial
Keyword(s):
2020 ◽
Vol 13
(1)
◽
pp. 443
Keyword(s):
Keyword(s):
Keyword(s):
2013 ◽
Vol 49
(6)
◽
pp. 1205-1215
◽
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
Vol 25
(6)
◽
pp. 1441-1449
◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 8
(4)
◽
pp. 332-339
◽
Keyword(s):